Alkermes Reports Positive Results


One of our Picks to Clicks for Q4 2016, Alkermes, announces positive topline results from its pivotal phase 3 study FORWARD-5 of ALKS 5461 for Major Depressive Disorder. See company press release. The stock was up over 25% on Friday. However, the stock could have been up more on this potential blockbuster drug, but investors are still worried that the FDA might not be convinced without another trial.

#ALKS

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon